ArticleClinical case reports2022

Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.

Alicia Roldán Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.